Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report

Anton Y. Peleg; Brian A. Potoski; Rhonda Rea; Jennifer Adams; Jigme Sethi; Blair Capitano; Shahid Husain; Eun J. Kwak; Sunil V. Bhat; David L. Paterson
January 2007
Journal of Antimicrobial Chemotherapy (JAC);Jan2007, Vol. 59 Issue 1, p128
Academic Journal
Objectives: Tigecycline has shown in vitro activity against Acinetobacter baumannii. Yet, published clinical experience with tigecycline use outside clinical trials is lacking. We describe, for the first time, bloodstream infection caused by tigecycline-non-susceptible A. baumannii occurring in patients receiving tigecycline for other indications. The possible mechanisms of resistance and pharmacokinetic limitations of the drug are addressed.Methods: The clinical records of involved patients were systematically reviewed. Tigecycline susceptibility testing was initially performed using the Etest method and confirmed by agar dilution. Involved isolates underwent PFGE and exposure to phenyl-arginine-β-naphthylamide (PAβN), an efflux pump inhibitor.Results: Two patients developed A. baumannii bloodstream infection while receiving tigecycline. Tigecycline was administered for other indications for 9 and 16 days, respectively, before the onset of A. baumannii infection. Patient 1 died of overwhelming A. baumannii infection and Patient 2 recovered after a change in antibiotic therapy. The MICs of tigecycline were 4 and 16 mg/L, respectively. Both isolates had a multidrug-resistant phenotype and were genotypically unrelated. After exposure to PAβN, the MICs reduced to 1 and 4 mg/L, respectively.Conclusions: To our knowledge, this is the first clinical description of bloodstream infection caused by tigecycline-non-susceptible A. baumannii. Such resistance appears to be at least partly attributable to an efflux pump mechanism. Given the reported low serum tigecycline levels, we urge caution when using this drug for treatment of A. baumannii bloodstream infection.


Related Articles

  • The evolution of the regulatory framework for antibacterial agents. Rex, John H.; Goldberger, Mark; Eisenstein, Barry I.; Harney, Carrie // Annals of the New York Academy of Sciences;Sep2014, Vol. 1323 Issue 1, p11 

    The rising tide of antibacterial resistance and the lack of a diverse, vibrant pipeline of novel antibacterial agents is a global crisis that impairs our ability to treat life-threatening infections. The recent introduction of a tiered approach to the regulatory framework in this area offers one...

  • Stop Costly Phase III Failures. Yue, Corinne Seng; Colucci, Philippe; Ducharme, Murray P. // Applied Clinical Trials;Jun2009, Vol. 18 Issue 6, Special section p4 

    The article discusses ways on how to prevent costly Phase III failures in clinical trials. High failure rates as attributed to safety and efficacy outcomes at the end of the process of drug development. It states that basic errors during the development process may be avoided using...

  • Bivalirudin: A Review of Pharmacology and Therapeutic Use. SCHOLLE, JENNIFER M.; WHITE, C. MICHAEL // Connecticut Medicine;Nov2010, Vol. 74 Issue 10, p595 

    The article offers information on the pharmacology and therapeutic use of bivalirudin, a synthetic 20-amino acid peptide analogue of the anticoagulant hirudin. The mechanism of action of bivalirudin is described. A discussion on its pharmacokinetics and pharmacodynamics is detailed. It...

  • Pharmacometrics: Alternative approach of quantitative pharmacology. Gayatri, Anggi; Setiabudy, Rianto // Pharmaceutical Sciences Asia;2019, Vol. 46 Issue 2, p63 

    The needs of understanding the pharmacokinetics and pharmacodynamics by researchers and physicians to give the best rational therapy for the patient is high. Pharmacokinetics and pharmacodynamics characteristics are usually obtained from phase one and phase two of clinical trials which are...

  • Correction: Allopregnanolone Preclinical Acute Pharmacokinetic and Pharmacodynamic Studies to Predict Tolerability and Efficacy for Alzheimer's Disease. null, null // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    No abstract available.

  • The Echinocandins: Comparison of Their Pharmacokinetics, Pharmacodynamics and Clinical Applications. Wagner, Claudia; Graninger, Wolfgang; Presterl, Elisabeth; Joukhadar, Christian // Pharmacology;2006, Vol. 78 Issue 4, p161 

    Caspofungin, micafungin and anidulafungin are three drugs of the echinocandin class of antifungals available for intravenous treatment of invasive candidiasis and aspergillosis. They exhibit high in vitro and in vivo activities against Candida spp. and Aspergillus spp. In various clinical...

  • Considerations in Undertaking a Clinical Development Program for Hospital-Acquired Bacterial Pneumonia and/or Ventilator-Associated Bacterial Pneumonia. Talbot, George H. // Clinical Infectious Diseases;8/1/2010 Supplement 1, Vol. 51, pS144 

    Achieving marketing authorization for an antimicrobial for the treatment of hospital-acquired bacterial pneumonia (HABP) and/or ventilator-associated bacterial pneumonia (VABP) is challenging because each clinical trial and each clinical development program must address the requirements of...

  • Trends in Research. Henderson, Lisa // Applied Clinical Trials;Jun2009, Vol. 18 Issue 6, p7 

    The article presents questions and answers related to trends in clinical research including the most important factor that sponsors consider in outsourcing clinical trials, important factors of in early phase outsourcing, and the diminishing lines between Phase I and Phase II trials.

  • In This Issue.  // Clinical Pharmacology & Therapeutics;Mar2015, Vol. 97 Issue 3, p195 

    An introduction is presented in which the editor discusses various reports within the issue on topics including the debate on the concept of adaptive licensing (AL), Physiologically based pharmacokinetic modeling in drug discovery, and model-based clinical trial design.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics